Compare Keel Infrastructure Corp. Common Stock (KEEL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keel Infrastructure Corp. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Keel Infrastructure Corp. Common Stock trades at $2.45 (market cap $1.77B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Keel Infrastructure Corp. Common Stock is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Keel Infrastructure Corp. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keel Infrastructure Corp. Common Stock for 3 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KEEL | MRVI | |
|---|---|---|
Market Cap | $1.77B | $972.90M |
Volume | 34,111,650 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $6.66 | $9.00 |
52-Week Low | $1.71 | $2.83 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $2.09B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KEEL trades at $2.87, down 2.71% on the day, reflecting a bearish technical trend amid weak financial performance. The company reported a net loss of $208.51M on $229.28M revenue in 2025, with negative profit margins and cash flow from operations. Despite this, analyst consensus is unanimously bullish with a $6.25 price target, citing progress in its HPC and AI data center strategy, including a recent partnership with PowerSecure for its Moses Lake campus.
The outlook hinges on successful execution of its data center pivot, offering significant upside if leasing targets are met, but high execution risk and persistent losses pose substantial threats to shareholder value. Liquidity remains supported by financing activities, yet profitability challenges and competitive pressures require careful monitoring.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Keel Infrastructure Corp. Common Stock
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
